What happened
Shares of Semler Scientific (NASDAQ: SMLR) are skyrocketing today, up by 19.1% as of 10:50 a.m. ET. The big gain came after the healthcare technology company announced its second-quarter results following the market close on Tuesday.
Semler reported Q2 revenue of $14.8 million, up 4% year over year and slightly above Wall Street estimates. The company posted earnings of $4.1 million, or $0.51 per diluted share. While this was lower than Semler's results from the prior-year period, it easily topped the consensus earnings estimate of $0.40 per share.
So what
Investors needed some good news from Semler. The healthcare stock had plunged 64% year to date prior to today's jump. But Semler's Q2 update was just what the doctor ordered.
The company's Q2 revenue was the highest quarterly revenue in its history. Even though earnings fell year over year, Semler has been profitable in every quarter since Q4 2017. The company also reported its biggest cash stockpile ever, with cash and cash equivalents totaling $40 million as of June 30, 2022.
This success was driven by Semler's QuantaFlo point-of-care test that's used in the diagnosis of cardiovascular diseases. CEO Doug Murphy-Chutorian said that the company had increased QuantaFlo orders from existing and new customers during Q2.
Now what
The second half of 2022 should be even better for Semler than the first. The company expects revenue growth in the second half will be between 14% and 21%. As a result, Semler projects full-year revenue will increase by between 9% and 14% year over year to $58 million to $60 million. The company's operations expenses should also be lower than previously anticipated because of increased sales organization efficiencies in the first half of the year.
10 stocks we like better than Semler Scientific
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Semler Scientific wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of July 27, 2022
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Semler Scientific. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
